AstraZeneca has also filed an oral SERD, camizestrant, targeting use of the drug in patients with advanced HR-positive breast ...

The results of the clinical trial mark a setback for the Swiss pharmaceutical company, which saw in the drug, giredestrant, a candidate to become a blockbuster treatment.

Roche, a global pharmaceuticals and diagnostics company, is acquiring Ignyta for $27 per share in an all-cash transaction. This corresponds to a total transaction value of $1.7 billion on a fully ...

An amylin-targeting medicine at the center of the companies’ multibillion-dollar alliance spurred less weight loss than ...

Syapse, an oncology-focused precision medicine company, entered into a multiyear strategic collaboration with Roche. Syapse will work with Roche, which includes both pharmaceutical and diagnostics ...

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. A regimen combining a new experimental Roche medicine ...

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at least a four-point improvement in SRI-4, a measure that assesses disease severity and symptoms; ...

Roche Holding AG and Zealand Pharma A/S shares plummeted Friday after their experimental obesity shot failed to meet industry ...

Foundation Medicine, a subsidiary of the giant Swiss drug maker Roche and one of the biggest biopharma employers in Massachusetts, is getting a new leader. Foundation announced Thursday that Dr. Brian ...

Emcure partners with Roche to enhance access to nephrology and transplant therapies for chronic kidney disease in India.

These companies have a lot more to offer than their prospects in the weight loss market.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Foundation Medicine, Inc., today announced the appointment of Roche executive, Dan Malarek, as Chief Executive Officer (CEO). Malarek succeeds Brian Alexander, M.D., ...